Recursion Pharmaceuticals (RXRX) Non-Current Assets (2020 - 2026)

Recursion Pharmaceuticals has reported Non-Current Assets for 7 years, with the latest figure at $630.0 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 12.64% year-over-year to $630.0 million; the trailing twelve-month figure through Mar 2026 stood at $2.7 billion (up 37.25% YoY), and the FY2025 full-year result was $661.3 million, down 9.95% from the prior year.
• Non-Current Assets for Q1 2026 stood at $630.0 million, down from $661.3 million in the prior quarter.
• The five-year high for Non-Current Assets was $734.3 million in Q4 2024, with the low at $114.9 million in Q1 2022.
• Historically, Non-Current Assets has averaged $363.3 million across 5 years, with a median of $235.7 million in 2023.
• Annual changes were most pronounced in 2024 — Non-Current Assets jumped 240.66% — and 2026, when it dropped 12.64%.
• Recursion Pharmaceuticals' Non-Current Assets stood at $131.5 million in 2022, then jumped by 63.96% to $215.6 million in 2023, then jumped by 240.66% to $734.3 million in 2024, then slipped by 9.95% to $661.3 million in 2025, then declined by 4.74% to $630.0 million in 2026.
• The last three Non-Current Assets figures came in at $630.0 million (Q1 2026), $661.3 million (Q4 2025), and $685.4 million (Q3 2025), per Business Quant data.